Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.

Fijalkowski I, Boudin E, Mortier G, Van Hul W.

Curr Osteoporos Rep. 2014 Sep;12(3):243-51. doi: 10.1007/s11914-014-0220-5. Review.

PMID:
24947952
2.

Lessons from sclerosing bone dysplasias.

Van Hul W.

Horm Res. 2007;68 Suppl 5:37-9. doi: 10.1159/000110472. Epub 2007 Dec 10. Review.

PMID:
18174704
3.

Targeting sclerostin as potential treatment of osteoporosis.

Papapoulos SE.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i119-22. doi: 10.1136/ard.2010.141150. Review.

PMID:
21339215
4.

MECHANISMS IN ENDOCRINOLOGY: Genetics of human bone formation.

Boudin E, Van Hul W.

Eur J Endocrinol. 2017 Aug;177(2):R69-R83. doi: 10.1530/EJE-16-0990. Epub 2017 Apr 5. Review.

5.

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis.

Appelman-Dijkstra NM, Papapoulos SE.

Drugs. 2015 Jul;75(10):1049-58. doi: 10.1007/s40265-015-0417-7. Review.

6.

Osteoporosis: now and the future.

Rachner TD, Khosla S, Hofbauer LC.

Lancet. 2011 Apr 9;377(9773):1276-87. doi: 10.1016/S0140-6736(10)62349-5. Epub 2011 Mar 28. Review.

7.

Molecular genetics of too much bone.

Janssens K, Van Hul W.

Hum Mol Genet. 2002 Oct 1;11(20):2385-93. Review.

PMID:
12351574
8.

Bone quality and osteoporosis therapy.

Martin RM, Correa PH.

Arq Bras Endocrinol Metabol. 2010 Mar;54(2):186-99. Review.

9.

[Newly developed drugs to improve bone strength].

Hagino H.

Clin Calcium. 2016 Jan;26(1):99-105. doi: CliCa160199105. Review. Japanese.

PMID:
26728536
10.

Potential new drug targets for osteoporosis.

Deal C.

Nat Clin Pract Rheumatol. 2009 Jan;5(1):20-7. doi: 10.1038/ncprheum0977. Review. Erratum in: Nat Clin Pract Rheumatol. 2009 Mar;5(3):174.

PMID:
19098925
11.

Halofuginone prevents estrogen-deficient osteoporosis in mice.

Deselm CJ, Zou W, Teitelbaum SL.

J Cell Biochem. 2012 Oct;113(10):3086-92. doi: 10.1002/jcb.24185.

12.

The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.

Yavropoulou MP, Xygonakis C, Lolou M, Karadimou F, Yovos JG.

Hormones (Athens). 2014 Oct-Dec;13(4):323-37. doi: 10.14310/horm.2002.1552. Review.

13.

New horizons in osteoporosis therapies.

Harsløf T, Langdahl BL.

Curr Opin Pharmacol. 2016 Jun;28:38-42. doi: 10.1016/j.coph.2016.02.012. Epub 2016 Mar 15. Review.

PMID:
26989807
14.

[Management of osteoporosis by using biochemical markers for bone turnover].

Mizunuma H.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:227-30. Review. Japanese. No abstract available.

PMID:
18159710
15.

[Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].

Jakob F, Genest F, Baron G, Stumpf U, Rudert M, Seefried L.

Unfallchirurg. 2015 Nov;118(11):925-32. doi: 10.1007/s00113-015-0085-9. Review. German.

PMID:
26471379
16.

The use of PTH in the treatment of osteoporosis.

Borba VZ, Mañas NC.

Arq Bras Endocrinol Metabol. 2010 Mar;54(2):213-9. Review.

17.

Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats.

Lama A, Santoro A, Corrado B, Pirozzi C, Paciello O, Pagano TB, Russo S, Calignano A, Mattace Raso G, Meli R.

PLoS One. 2017 Feb 3;12(2):e0171276. doi: 10.1371/journal.pone.0171276. eCollection 2017.

18.

Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.

Burch J, Rice S, Yang H, Neilson A, Stirk L, Francis R, Holloway P, Selby P, Craig D.

Health Technol Assess. 2014 Feb;18(11):1-180. doi: 10.3310/hta18110. Review.

19.

Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.

Gallagher JC, Sai AJ.

Maturitas. 2010 Apr;65(4):301-7. doi: 10.1016/j.maturitas.2010.01.002. Epub 2010 Jan 29. Review.

20.

Bisphosphonates for the prevention and treatment of osteoporosis.

Maraka S, Kennel KA.

BMJ. 2015 Sep 2;351:h3783. doi: 10.1136/bmj.h3783. Review.

PMID:
26333528

Supplemental Content

Support Center